SynthesisBMC gastroenterology2026
Non-HDL-to-HDL-cholesterol ratio and metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and is linked to dyslipidemia and cardiometabolic dysfunction. The non-HDL cholesterol to HDL cholesterol ratio (NHHR) has emerged as a composite lipid biomarker that reflects the balance between atherogenic and anti-atherogenic lipoproteins and may have utility in MASLD risk stratification. However, the strength and consistency of the association between NHHR and MASLD remain uncertain. This systematic review and meta-analysis aimed to synthesize the available evidence regarding the association between NHHR and MASLD and evaluate its diagnostic performance.
methodsA systematic search of PubMed, Embase, and Google Scholar was conducted from database inception through January 2026 in accordance with PRISMA guidelines. Original human studies evaluating the relationship between NHHR and MASLD were included. Random-effects meta-analyses were performed to calculate pooled standardized mean differences (SMDs) in NHHR between individuals with and without MASLD, pooled odds ratios (ORs) for MASLD according to NHHR levels, and pooled area under the receiver operating characteristic curve (AUC) to evaluate diagnostic performance. Study quality was assessed using the Newcastle-Ottawa Scale.
resultsTwenty-four studies were included in the systematic review, and 19 studies comprising 120,985 participants were included in the quantitative synthesis. Individuals with MASLD had significantly higher NHHR values than controls (pooled SMD = 1.01, 95% CI: 0.17-1.84; p = 0.018). Higher NHHR levels were associated with increased odds of MASLD (pooled OR = 1.56, 95% CI: 1.25-1.96; p < 0.001). A clear dose-response relationship was observed, with progressively greater odds of MASLD across increasing NHHR categories: OR = 1.60 (95% CI: 1.21-2.13) for Q2/T2 versus Q1/T1, OR = 1.87 (95% CI: 1.67-2.09) for Q3 versus Q1, and OR = 2.19 (95% CI: 1.77-2.70) for Q4/T3 versus Q1/T1. Twelve studies evaluating diagnostic accuracy demonstrated a pooled AUC of 0.73 (95% CI: 0.70-0.75), indicating moderate discriminatory ability of NHHR for identifying MASLD.
conclusionsNHHR is significantly associated with MASLD and demonstrates a graded relationship with disease association, whereby higher NHHR levels correspond to progressively greater odds of MASLD. Furthermore, NHHR exhibits moderate diagnostic accuracy for identifying MASLD. As a simple, inexpensive, and widely available metric derived from routine lipid testing, NHHR may serve as a practical adjunctive biomarker for MASLD risk stratification and may help identify individuals who could benefit from further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.